[On July 13, 2011] An eighty-eight-year-old man whom I'll call Alan A. collapsed from a massive heart attack at his home outside Philadelphia. He survived and spent two weeks in the intensive care unit of Virtua Marlton Hospital. Virtua Marlton was part of a four-hospital nonprofit chain that, in its 2010 federal filing, had reported gross revenue of $633.7 million and an operating profit of $91 million. Alan then spent three weeks at a nearby convalescent care center.
...
Medicare made quick work of Alan's $268,227 in chargemaster bills from the hospital and convalescent center, paying just $43,320. Except for $100 in incidental expenses, Alan paid nothing because 100 percent of inpatient hospital care is covered by Medicare.
The ManorCare convalescent center, which Alan later told me gave him "good care" in an "OK but not luxurious room," got paid $11,982 by Medicare for his three-week stay. That amounts to about $571 a day for all of Alan's physical therapy, lab tests, and other services. As with all hospitals in nonemergency situations, ManorCare did not have to accept Medicare patients and their discounted rates. But it did accept them. In fact, it welcomed them and encouraged doctors to refer them.
Healthcare providers may grouse about Medicare's fee schedules, which they claim they lose money on. But Medicare's payments must have been producing a profit for ManorCare. It was part of a for-profit chain owned by Carlyle Group, a blue-chip private-equity firm.
About a decade before his July 2011 heart attack Alan had been diagnosed with non-Hodgkin's lymphoma ... Through a family friend, he got an appointment with one of the lymphoma specialists at the Memorial Sloan Kettering Cancer Center in New York ... A decade later, Alan was still in remission, traveling up to Sloan Kettering every six weeks to be examined by the doctor who saved his life and to get a transfusion of Flebogamma, a drug that bucks up the immune system.
With some minor variations each time, Sloan Kettering's typical bill for each visit was the same as or similar to the $7,346 bill he received during his visit there in the summer of 2011. It included $340 for a session with the doctor. His actual out of pocket cost for each session was a fraction of that ... $50.
...
Not counting the doctor's separate $340 bill, Sloan Kettering's bill for the transfusion was $7,006. In addition to a few hundred dollars in miscellaneous items, the two basic Sloan Kettering charges were $414 per hour for five hours of the nurse's time for administering the Flebogamma and a $4,615 charge for the Flebogamma.
According to Alan, the nurse generally handled three or four patients at a time. That would mean Sloan Kettering was billing more than $1,200 an hour for that nurse. When I asked Paul Nelson, Sloan Kettering's director of financial planning, he explained that 15 percent of these charges was meant to cover overhead and indirect expenses, 20 percent was meant to be profit that would cover discounts for Medicare or Medicaid patients, and 65 percent covered direct expenses. [That's still $800 an hour for the nurse].
...
Bottom line: Sloan Kettering got paid $302 by Medicare for about $2,400 worth of its chargemaster charges, and Alan ended up paying $6.
...
A Grifols spokesman would not discuss what is cost Grifols to produce and ship Alan's dose [of Flebogamma]. But he did say that the average production for its bioscience prodcuts, Felbogamma included, was approximately 55 percent of what it sells them for. However, a doctor familiar with the economics of cancer care drugs told me that plasma products typically have some of the industry's higher profit margins. He estimated that the Flebogamma dose for Alan - which Sloan Kettering seemed to have bought from Grifols for $1,400 to $1,600 and sold to Medicare for $2,123 [Medicare pays for drugs what the average sales price is for the drug company, plus 6%]- can't cost more than $200 or $300 to collect, process, test, and ship. That would be a 460 to 800 percent markup.